Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™

Rhea-AI Summary

Polyrizon (Nasdaq: PLRZ) announced completion of the branding process for its PL-14 allergy blocker, which will be marketed as NASARIX™. NASARIX™ uses Polyrizon's proprietary Capture and Contain™ (C&C) hydrogel intranasal spray technology intended to form a physical barrier against allergens and viruses. The company completed trademark screening and linguistic evaluations across the U.S. and European markets to support brand viability and regulatory alignment. Management framed the naming as a milestone toward commercial readiness and said NASARIX™ introduction will align with ongoing clinical and regulatory progress.

Market Reality Check

$12.79 Last Close

Volume Volume 63,965 is at 0.28x the 20-day average of 228,478, indicating subdued trading before this news. low

Technical Price 12.38 is trading below the 200-day MA of 123.25, reflecting a longer-term downtrend into this branding update.

Peers on Argus 1 Up

PLRZ’s -6.81% move came as peers showed mixed performance: TTNP -3.96%, ADTX -6.62%, SXTP -5.21% declined, while ENSC +4.90% and SILO +3.78% rose, pointing to stock-specific factors rather than a unified biotech move.

Common Catalyst Some peer news, such as ENSC’s EU patent for its ADHD therapy, reflects broader innovation in small-cap biotech but does not directly relate to Polyrizon’s branding announcement.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Jan 05	Preclinical data PL-14	Positive	-0.8%	In-vitro data showing significantly reduced Der p 1 transfer versus HPMC comparator.
Jan 02	Product positioning	Positive	+50.2%	PL-16 presented as complementary nasal barrier during severe 2025–2026 U.S. flu season.
Dec 29	Strategic update	Positive	-1.4%	Board authorizes exploration of revenue-generating real assets leveraging strong cash and no debt.
Dec 19	Regulatory step PL-16	Positive	-6.7%	Submission of Pre-Request for Designation to FDA for PL-16 viral blocker product.
Dec 11	Preclinical data naloxone	Positive	+11.5%	Naloxone hydrogel showed strong mucoadhesion and permeation comparable to reference product.

Pattern Detected

Recent news has often been positive scientifically, yet price reactions skew negative, suggesting a tendency for good news to be sold or underappreciated.

Recent Company History

Over the past month, Polyrizon reported several positive developments. On Dec 11, 2025, preclinical naloxone hydrogel data drove an 11.46% rise. A Dec 19 Pre-RFD filing for PL-16 was followed by a -6.73% move. Exploration of revenue-generating real assets on Dec 29 saw a modest -1.35% reaction. Flu-season positioning for PL-16 on Jan 2 produced a strong +50.18% gain. New PL-14 preclinical results on Jan 5 led to a slight -0.78% decline. Today’s NASARIX branding fits the ongoing push toward commercialization of PL-14.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-11-07

$50,000,000 registered capacity

An effective Form F-3 shelf filed on Nov 7, 2025 allows Polyrizon to offer up to $50,000,000 of securities, including ordinary shares, warrants, and units, for general corporate purposes and potential strategic opportunities once effective.

Market Pulse Summary

The stock moved +8.4% in the session following this news. A strong positive reaction aligns with Polyrizon’s recent emphasis on advancing PL-14 from preclinical success toward commercialization. Branding PL-14 as NASARIX™ formalized its market identity and supported future partnering and launch efforts. Past news showed mixed price responses to positive updates, so a large gain could have reflected renewed confidence in commercialization plus the optionality of a $50,000,000 shelf, but sustainability would still have depended on clinical and regulatory milestones.

Key Terms

intranasal medical

"a pre-clinical-stage biotechnology company developing intranasal protective solutions"

Administration or delivery of a drug or vaccine through the nose, typically via a spray or drops that are absorbed by the nasal tissues. For investors, intranasal products can matter because they often offer easier, needle-free use, faster onset of effect, and potential cost or compliance advantages that can widen a product’s market and affect regulatory review, manufacturing complexity, and commercial prospects — similar to how a convenient app can outsell a clunky desktop program.

hydrogel medical

"hydrogel technology, an innovative intranasal spray formulation designed to create"

A hydrogel is a soft, jelly-like material made mostly of water combined with a network of flexible, supportive molecules. Its unique ability to hold large amounts of water while remaining stable makes it useful in various medical, industrial, and consumer applications. For investors, innovations involving hydrogels can signal growth opportunities in sectors like healthcare, biotechnology, and advanced materials.

trademark screening technical

"conducted comprehensive trademark screening and linguistic evaluations across the U.S."

Trademark screening is the process of checking a proposed name, logo or slogan against existing trademarks and brand uses to spot conflicts or confusing similarities before launch. For investors it matters because conflicts can lead to lawsuits, forced rebranding, lost sales or blocked market entry, all of which can damage value and create unexpected costs — like finding out a chosen username is already taken after you've built a following.

regulatory pathway regulatory

"as we advance toward upcoming clinical and regulatory milestones." Polyrizon expects"

A regulatory pathway is the official process a product or service must follow to gain approval from government authorities before being offered to the public. It outlines the steps, tests, and reviews needed to demonstrate safety, effectiveness, or compliance. For investors, understanding the regulatory pathway helps assess how quickly and easily a product can reach the market and generate revenue.

clinical progress medical

"introduced in alignment with its ongoing clinical progress and regulatory pathway."

Clinical progress describes measurable advances in the testing and approval pathway for a medical therapy or diagnostic during human studies, such as reaching safety or effectiveness milestones, completing trial phases, or receiving regulatory clearances. For investors it signals reduced scientific and regulatory risk and clearer timelines for potential commercial revenue, much like a building moving from blueprint to finished floors: each completed stage makes the final outcome more likely and easier to value.

AI-generated analysis. Not financial advice.

As part of the branding process, Polyrizon conducted comprehensive trademark screening across the U.S. and European markets

Raanana, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) --  Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has completed the branding process for its PL-14 allergy blocker, which will be marketed under the brand name NASARIX™.

NASARIX™ is based on Polyrizon’s proprietary Capture and Contain™ (C&C) hydrogel technology, an innovative intranasal spray formulation designed to create a protective physical barrier against allergens and viruses. Establishing the NASARIX™ brand represents an important milestone in Polyrizon’s pathway toward future commercialization and supports the Company’s ability to communicate the product’s differentiated benefits clearly and effectively to patients, healthcare professionals, and commercial partners.

As part of the branding process, Polyrizon conducted comprehensive trademark screening and linguistic evaluations across the U.S. and European markets to support brand viability and alignment with regulatory and market requirements.

Tomer Izraeli, CEO of Polyrizon, commented, "Selecting NASARIX™ as the brand name for PL-14 allergy blocker reflects our commitment to commercial readiness and our focus on building a strong and recognizable identity in the allergy and respiratory health markets. This is a key step as we advance toward upcoming clinical and regulatory milestones."

Polyrizon expects NASARIX™ to be introduced in alignment with its ongoing clinical progress and regulatory pathway.

About Polyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its pathway toward future commercialization, its commitment to commercial readiness, its focus on building a strong and recognizable identity in the allergy and respiratory health markets and its expectation that NASARIX™ will be introduced in alignment with its ongoing clinical progress and regulatory pathway. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Contacts:

Michal Efraty

Investor Relations

IR@polyrizon-biotech.com

FAQ

What is NASARIX™ and which company owns the brand (PLRZ)?

NASARIX™ is the brand name for PL-14, an intranasal allergy blocker developed by Polyrizon (Nasdaq: PLRZ).

When did Polyrizon announce completion of the NASARIX™ branding?

Polyrizon announced completion of the NASARIX™ branding on January 8, 2026.

What technology does NASARIX™ use and what is its intended purpose?

NASARIX™ is based on the Capture and Contain™ (C&C) hydrogel intranasal spray, designed to create a physical barrier against allergens and viruses.

Has Polyrizon completed regulatory approval or launched NASARIX™ commercially?

No; the company said NASARIX™ introduction will align with its ongoing clinical progress and regulatory pathway, not that approvals or a commercial launch are complete.

Did Polyrizon perform trademark checks for NASARIX™ in major markets?

Yes; Polyrizon conducted comprehensive trademark screening and linguistic evaluations across the U.S. and European markets to support brand viability.